Selegiline in the treatment of behavioural disturbance in Alzheimer'sdisease
B.A. Lawlor
Bok Engelsk 1997
| Utgitt | 1997
|
|---|---|
| Omfang | Side 319- 322
|
| Opplysninger | Objective. The purpose of this study was to examine the behaviouraland cognitive effects of selegiline in a group of moderatelybehaviourally disturbed AD patients.Design. This was a 14-week randomized double-blind placebo-controlledstudy of selegiline (10 mg) and placebo.Setting. An outpatient clinic in an urban-based tertiary referralcentre in the USA.Patients. Twenty-five outpatients meeting NINCDS criteria forprobable Alzheimer's disease with associated behaviouraldisturbance.Measures. The Brief Psychiatric Rating Scale (BPRS), the DementiaMood Assessment Scale (DMAS) and the Alzheimer Disease AssessmentScale (Cognitive) (ADAS-COG).Results. In the primary analysis, improvement on the BPRS and DMASscores with selegeline treatment did not reach statisticalsignificance. A secondary analysis using a parallel design showed asignificant benefit of drug treatment on BPRS scores with a trendtowards improvement on the DMAS. Among the 10 subjects who could betested, there was a significant improvement in cognitive function onthe ADAS-COG with selegiline compared to placebo.Conclusions. Short-term selegiline treatment produced an improvementin behaviour and had a significant effect on cognition in a subset oftestable patients. ((C) 1997 by John Wiley & Sons, Ltd.)
|
| Emner |
